Dallas, Texas, June 15, 2020 (GLOBE NEWSWIRE) -- The Global Preimplantation Genetic Testing Market Size 2018, By Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism) Region and Forecast 2019 to 2025 study provides an elaborative view of historic, present and forecasted market estimates.

Request a pdf sample @https://www.adroitmarketresearch.com/contacts/request-sample/1483

Adroit Market Research report on global preimplantation genetic testing market gives a holistic view of the market from 2015 to 2025, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2015 to 2017, with the base year of estimation as 2018 and forecast from 2019 to 2025. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global preimplantation genetic testing market have been studied in detail.

The global preimplantation genetic testing market is projected to reach USD 1,147.9 million by 2025, growing at a CAGR of 11.8%. Increasing rate of infertility worldwide, growing number of fertility clinics across the globe, public-private investments in the field of preimplantation genetic testing, high risk of chromosomal abnormalities in the fetus with increasing maternal age and technological advancements in the field of genetic analysis are the factors driving the growth of the preimplantation genetic testing market.

Browse the complete report with Table of Contents and List of Figures @https://www.adroitmarketresearch.com/industry-reports/preimplantation-genetic-testing-market

Preimplantation genetic testing is a process in which embryos developed outside the womb are tested for particular genetic characteristics, usually genetic abnormalities that cause serious disease, before being transferred to a womans uterus. Preimplantation genetic testing owes its existence to advances in the world of reproductive medicine and genetics that occurred in the late 20th century. Though initially developed as a means to detect serious genetic conditions, preimplantation genetic testing can be used for other purposes. In fact, virtually any of the hundreds of genetic tests now commercially available, and the many more in development, could be used to test embryos. However, socio-ethical concerns regarding preimplantation genetic testing is a major challenge surrounding the market.

The global preimplantation genetic testing market is categorized based on test type and technology. Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization and single-nucleotide polymorphism. Next-generation sequencing held the largest market share in 2018. The benefits of NGS include:

It allows simultaneous analysis of 24 chromosomes with higher resolution It offers the possibility to analyze chromosomal aneuploidy and monogenic diseases (caused by mutations in a single gene) separately or simultaneously in a single assay Reduced analysis time, avoiding the need to freeze the embryos while awaiting results It allows the simultaneous analysis of several embryos on a single test which directly affects the cost of analysis.

Direct purchase the singe user copy @https://www.adroitmarketresearch.com/researchreport/purchase/1483

In 2018, North America was the largest market for preimplantation genetic testing owing to rising number of IVF procedures and substantial adoption of genomic techniques. Moreover, Asia Pacific is projected to grow at a highest pace during the forecast period. Key players of the preimplantation genetic testing market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology among others.

Major points from Table of Contents:1. Introduction2. Research Methodology3. Market Outlook4. Preimplantation genetic testing Market by Test Type, 2015-2025 (USD Million)5. Preimplantation genetic testing Market by Technology, 2015-2025 (USD Million)6. Preimplantation genetic testing Market by Region 2015-2025 (USD Million)7. Competitive Landscape8. Company Profiles9. Appendix

Access research repository of Upcoming Reports @ https://adroitmarketresearch.com/upcoming.html

About Us:Adroit Market Research is a global business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Link:
Preimplantation Genetic Testing Market to grow at 11.8% CAGR to hit US $1,147.9 million by 2025 Insights on Trends, Growth Drivers, Key Stakeholders,...

Comments are closed.